孟详喻简介
姓 名： 孟详喻
性 别：男
最高学位：博士
职 称：副教授
职 务：无
mail ： mengxy_whu@163.com
电 话：15827268359
研究方向：干湿结合的疾病机制与转化研究
个人简介：
孟详喻，1990年生，湖北恩施人，土家族，博士，副教授，硕士研究生导师。本硕连读毕业于武汉大学（临床医学七年制中法班），期间先后赴法国洛林大学（法国政府奖学金资助）和日本北海道大学访问学习。博士毕业于巴黎萨克雷大学（ARWU排名全球12，THE排名全球64），师从膀胱癌领军学者F. Radvanyi教授，从事膀胱癌肿瘤生物学研究。
中国农工民主党党员。
省级人才计划入选者。
任湖北省生物信息学会理事、欧洲肿瘤内科学会ESMO会员、全法中国科技工作者协会会员、亚太生物医学免疫学会血液学专委会委员、湖北省医学生物免疫学会血液学专委会与青年委员会委员。《临床内科杂志》通讯编委、Phenomics青年编委、iMeta青年编委、Oncology and Translational Medicine青年编委。Advanced Science、British Journal of Psychiatry、 Haematologica、HemaSphere、Journal of Advanced Research、Biomarker Research、MedComm、Clinical and Translational Medicine、Briefings in Bioinformatics、Scientific Data、Journal of Agricultural and Food Chemistry等数十本SCI期刊审稿人。
以第一/共一/通讯作者在European Urology (IF: 25.3，中科院1区top；3篇，含1篇封面论文)、Genome Medicine (IF: 10.4，中科院1区top)、Molecular Cancer (IF: 27.7，中科院1区top)、Advanced Science (IF: 14.3，中科院1区top)、Journal of Hematology & Oncology (IF: 29.5，中科院1区top) 、Theranostics (IF: 12.4，中科院1区top)、Clinical Chemistry (IF: 7.1，ADLM会刊，医学检验技术第一刊，中科院小类1区)、Journal for ImmunoTherapy of Cancer (IF: 10.3，中科院1区top) 、Advanced Healthcare Materials (IF: 10.0) 、Clinical and Translational Medicine (IF: 7.9)等高影响力期刊发表论文多篇，总引用>1,700，H-index 25。
(Google Scholar，https://scholar.google.com/citations?hl=en&user=JQYDHSkAAAAJ&view_op=list_works&sortby=pubdate)
通晓英（TOEFL iBT, CEFR C1）、法（TEF, CECR B2）、日（JLPT, N1）三门外语。
主持、参与的项目：
1. 湖北省高层次人才项目，楚天英才计划“楚天学者”，主持；
2. 法国国家健康与医学研究院（INSERM）ITMO Cancer AVIESAN Soutien pour la formation à la recherche fondamentale et translationnelle en Cancérologie博士基金项目，21.5万欧元，主持；
3. 国家自然科学基金青年项目，APOBEC3A驱动膀胱癌发生发展的动物模型及其机制研究，30万元，主持；
4. 国家自然科学基金面上项目，FGFR3突变介导受体过度激活和免疫抑制诱导膀胱癌发生和治疗耐药的分子机制，49万元，参与（2/7）；
5. 湖北省自然科学基金青年项目，APOBEC3A驱动膀胱癌发生和恶性进展的体内机制研究，5万元，主持；
6. 教育部学位与研究生教育发展中心主题案例项目，利用多组学技术研究土家医道地药材治疗阿尔兹海默病的有效成分及其作用机制研究案例，参与（3/6）；
7. 湖北民族大学博士科研启动基金及省级重点实验平台开放课题等多项，主持。
科研教学成果及奖励：
1. “基于尿液cfDNA的膀胱癌早筛液体活检关键技术及试剂盒研发”，第五届全国设备管理与技术创新成果二等奖，2022，中国设备管理协会.
2. “优福能—膀胱癌早筛尖端方案”，2021年中国国际“互联网+”大学生创新创业大赛国家级铜奖，2021，中国国际“互联网+”大学生创新创业大赛组织委员会.
公开发表论文、教材、专著及课程建设：
论文（*，通讯；#，第一/共一）：
Xiang-Yu Meng#. Cyclic enrichment of urinary exosomes using a MOF-on-MOF-based asymmetric impinging streams chip for bladder cancer diagnosis and prognosis prediction. Adv Healthc Mater. 2025, in press. (IF: 10.0，中科院2区).
Xiang-Yu Meng#,*. Gene and pathway analysis of genome-wide genetic associations of bladder cancer. Curr Urol. 2025, in press. (IF: 0.9，中科院4区).
Xiang-Yu Meng*. SysNatMed: rational natural medicine discovery by systems genetics. Front Pharmacol. 2025:1496061 (IF: 4.4, 中科院3区).
Xiang-Yu Meng*. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications. Mol Cancer. 2024:265 (IF: 27.7, 中科院1区top)
Xiang-Yu Meng#. Machine learning-based detection of bladder cancer by urine cfDNA fragmentation hotspots that capture cancer-associated molecular features. Clin Chem. 2024, 70(12):1463-1473 (IF: 7.1, ADLM official journal, 中科院小类1区).
Xiang-Yu Meng*. Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns. Adv Sci (Weinh). 2024:e2308243 (IF: 14.3, 中科院1区 top).
Xiang-Yu Meng#,*. Sex bias in FGFR3 somatic mutations in bladder cancer. Oncol Trans Med. 2024, 10(5): 252-256 (CSTPCD).
Xiang-Yu Meng*. Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype. Theranostics. 2024, 14(8):3104-3126 (IF: 12.4, 中科院1 区top).
Xiang-Yu Meng*. The underexplored role of APOBEC3 enzymes in autoimmune diseases. Rheumatology (Oxford). 2024, 63(6):e166-e167 (IF: 4.7, 中科院2区).
Xiang-Yu Meng*. Landscape of urine biomarkers for bladder cancer: molecular function, cell-of-origin, and bibliometric trend. Oncol Trans Med. 2024, 10(3):132-142 (CSTPCD).
Xiang-Yu Meng#,*. Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed. Epigenomics. 2023, 15(22):1175-1178 (IF: 3.0, 中科院4区).
Xiang-Yu Meng#,*. Historical pathogen-driven selection may contribute to contemporary ethnic difference in bladder cancer susceptibility. Bladder Cancer. 2023, 9(3): 211-216 (IF: 1.0, 中科院4区; BCAN official journal)
Xiang-Yu Meng#,*. Comments on “Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer”. Int J Cancer. 2023, 153(8):1543-1544 (IF: 5.7, 中科院2区).
Xiang-Yu Meng#,*. NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors. J Immunother Cancer. 2023, 11(6):e007255 (IF: 10.3, 中科院1区 top).
Xiang-Yu Meng*. The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer. J Transl Med. 2023, 21(1):298 (IF: 6.1, 中科院2 区top).
Xiang-Yu Meng#,*. “Paradoxical neoantigenic mutations”: not simply a driver vs passenger dualism. Br J Cancer. 2023, 129(1):1-2 (IF: 6.4, 中科院2 区top).
Xiang-Yu Meng#. FGFR3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias. Eur Urol. 2023, 83(1):70-81 (IF: 25.3, 中科院1 区top).
Xiang-Yu Meng*. Dynamic gene screening enabled identification of a 10-gene panel for early detection and progression assessment of gastric cancer. Comput Struct Biotechnol J. 2022, 21:677-687. (IF: 4.4, 中科院3区)
Xiang-Yu Meng*. Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer. J Hematol Oncol. 2022, 15(1):19 (IF: 29.5, 中科院1区 top).
Xiang-Yu Meng#,*. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 2020, 12(1):85 (IF: 10.4, 中科院1区 top; Feature).
Xiang-Yu Meng*. ΔNp63 drives epithelial differentiation in glioma. Clin Transl Med. 2020, 10(4):e165 (IF: 7.9, 中科院2区 top).
Xiang-Yu Meng#. Estimation and projection about the standardized prevalence of osteoporosis in mainland China. Calcif Tissue Int. 2020, 106(2):131-146 (IF: 3.3, 中科院3区).
Xiang-Yu Meng#. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13. Eur Urol. 2020, 77(1):e24-e25 (IF: 25.3, 中科院1区 top).
Xiang-Yu Meng#. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur Urol. 2019, 76(1):9-13 (IF: 25.3, 中科院1区 top; Cover).
Xiang-Yu Meng#. The role of COL5A2 in patients with muscle-invasive bladder cancer: a bioinformatics analysis of public datasets involving 787 subjects and 29 cell lines. Front Oncol. 2019, 8:659 (IF: 3.5, 中科院3区).
Xiang-Yu Meng*. Long-term efficacy of maintenance therapy for multiple myeloma: A quantitative synthesis of 22 randomized controlled trials. Front Pharmacol. 2018, 9:430 (IF: 4.4, 中科院3区).
Xiang-Yu Meng*. Bortezomib, thalidomide, and dexamethasone (VTD) induction results in better overall survival than adriamycin, thalidomide, and dexamethasone (ATD) induction in previously untreated myeloma patients eligible for transplants. Acta Haematol. 2017, 137(4):207-208 (IF: 1.7, 中科院4区).
Xiang-Yu Meng*. La relation entre la récurrence de la tumeur et les polymorphismes génétiques de hGPX1 et NRAMP1 chez les patients atteints du cancer superficiel de la vessie: une méta-analyse. Pan Afr Med J. 2017, 27: 270 (in French).
Xiang-Yu Meng*. Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/β-catenin signaling. Ann Hematol. 2016, 95(11):1787-93 (IF: 3, 中科院3区).
教材及专著：
《DK人体百科（涂色版）》，2019，北京科学技术出版社，主译
《人体筋膜系统功能学图谱》，2017，北京科学技术出版社，副主译
《应用STATA做Meta分析》，2016，中国协和医科大学出版社，编者
《循证临床实践指南的研发与评价》，2016，中国协和医科大学出版社，编者
《R与Meta分析》，2016，军事医学科学出版社，编者